Morningstar Downgrades Sequoia Fund On Day Michael Pearson Gets Congressional Subpoena – ValueWalk Premium
Sequoia Fund

Morningstar Downgrades Sequoia Fund On Day Michael Pearson Gets Congressional Subpoena

Sequoia Fund, which is known to highly value management teams when evaluating stock picks for its long-only mutual fund, lost big on Valeant Pharmaceuticals, a company with some of the most significant management problems in recent memory. Sequoia Fund had a management shake-up of its own recently. This management reshuffling, and its concentrated bet on the management team at Valeant Pharmaceuticals, have led to a downgrade by investment . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The top investors are reading ValuewalkPremium.

Click here to learn why

0